前沿生物表示，公司营业收入主要来自抗HIV创新药艾可宁®代理产品缬康韦®及报告期内获批的远红 外治疗贴的销售收入，扣非归母净利润减亏则是因为去年营业收入增长以及期间费用降低所致。 业绩预告显示，2025年，前沿生物投入研发费用约13，800.00万元到14，500.00万元，同比增加0.58% 到5.68%，主要是公司聚焦小核酸新药研发及其他新药的早期研发。 据了解，目前，前沿生物正逐步形成梯度化、多层次的研发管线布局，以抗病毒业务为基础支撑，以小 核酸创新药为核心发展主线，并以高端仿制药业务作为稳健补充。 报告期内，前沿生物还启动了FB2004的临床前研究工作，FB2004是一款新型干扰素-α2突变体，由复旦 大学与公司共同组建的"病毒感染功能性治愈校企联合实验室"研发。 1月30日晚间，前沿生物披露2025年度业绩预告。 另外，报告期内，公司持续推进FB4001的发补研究工作；FB3002，洛索洛芬钠热熔胶贴剂仿制药，用 于治疗肌肉骨骼关节痛，已向国家药监局提交仿制药上市许可申请并获得受理，目前处于审评阶段，公 司全资子公司齐河前沿生物药业有限公司已获得FB3002产品的生产许可证。 公司预计2025年度 ...

Core Insights - Frontline Bio (688221.SH) reported steady growth in performance for the first three quarters of 2025, achieving revenue of 103.37 million yuan, a year-on-year increase of 12.80% [1] - In Q3 2025, revenue reached 44.73 million yuan, showing a significant quarter-on-quarter growth of 47.58%, driven primarily by the sales of the innovative anti-HIV drug Aikening® and the agency product Viread® [1] - The company has increased its R&D investment, with R&D expenses amounting to 83.87 million yuan in the first three quarters, focusing on the small nucleic acid drug field and advancing long-acting anti-HIV drugs and high-end generics [1] Small Nucleic Acid Drug Development - The company is developing two small nucleic acid drugs, FB7013 and FB7011, targeting complement diseases, both of which have First-in-Class potential [2] - FB7013 targets the MASP-2 pathway and has shown promising preclinical results, with a single subcutaneous injection maintaining target protein reduction for 16 weeks in healthy monkeys, and is expected to submit an IND application by the end of 2025 [2] - FB7011, a dual-target drug, has demonstrated over 95% inhibition efficiency for both target proteins in preclinical studies, with significant improvements in key indicators in IgA nephropathy models, and is also expected to have a favorable safety profile [3] Upcoming Events and Future Directions - The company will present the latest preclinical efficacy data for FB7011 and FB7013 at the 2025 ASN Kidney Week in Houston, a leading global nephrology conference [3] - Additional small nucleic acid drug developments include FB7023 for dyslipidemia, which has completed pharmacological studies in transgenic mice, and early-stage products targeting hyperuricemia, tumors, and type 2 diabetes, all of which are in preclinical stages [4] - The company aims to leverage its research capabilities showcased at international conferences to enhance product competitiveness and continue breakthroughs in treatment options for complement and metabolic diseases [4]